Physician profile
Ryan Scott Brooks
NPI 1306228473
$1,718.52
in general payments reported to CMS, 2019-2025
20 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $199 · 2023: $488 · 2024: $558 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $372.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $255.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $243.66 | 2022-2023 | Proclaim |
| Pfizer INC. | $147.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.64 | 2023-2025 | Breztri, Airsupra |
| Vericel Corporation | $117.60 | 2024 | Maci |
| Lilly USA, LLC | $87.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $70.42 | 2023-2024 | Xarelto |
| Dynavax Technologies Corporation | $34.43 | 2025 | Heplisav-B |
| Cranial Technologies, INC | $33.68 | 2024 | Doc Band |
| Abbvie INC. | $33.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.11 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $30.08 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $23.76 | 2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $22.92 | 2025 | Jatenzo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $22.15 | 2024 | Xyosted |
| Axsome Therapeutics, INC. | $18.69 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $14.65 | 2025 | Eliquis |
| Amgen INC. | $14.31 | 2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.84 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.